Intracoronary optical coherence tomography and histology of overlapping everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: the potential implications for clinical practice.

[1]  Patrick W Serruys,et al.  Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy? , 2012, European heart journal.

[2]  G. Stone,et al.  Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis , 2012, The Lancet.

[3]  Yiannis S. Chatzizisis,et al.  Role of endothelial shear stress in stent restenosis and thrombosis: pathophysiologic mechanisms and implications for clinical translation. , 2012, Journal of the American College of Cardiology.

[4]  R. Whitbourn,et al.  Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-eluting scaffolds using optical coherence tomography. , 2011, JACC. Cardiovascular interventions.

[5]  P. Serruys,et al.  Delayed coverage in malapposed and side-branch struts with respect to well-apposed struts in drug-eluting stents: in vivo assessment with optical coherence tomography. , 2011, Circulation.

[6]  Bernard Chevalier,et al.  Angiographic geometric changes of the lumen arterial wall after bioresorbable vascular scaffolds and metallic platform stents at 1-year follow-up. , 2011, JACC. Cardiovascular interventions.

[7]  R. Virmani,et al.  Optical coherence tomography (OCT) of overlapping bioresorbable scaffolds: from benchwork to clinical application. , 2011, EuroIntervention.

[8]  P. Serruys,et al.  Tissue coverage of a hydrophilic polymer-coated zotarolimus-eluting stent vs. a fluoropolymer-coated everolimus-eluting stent at 13-month follow-up: an optical coherence tomography substudy from the RESOLUTE All Comers trial , 2011, European heart journal.

[9]  P. Serruys,et al.  Delineating the Numerous Causes of Drug-Eluting Stent Restenosis , 2011 .

[10]  Bernard Chevalier,et al.  Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. , 2011, Journal of the American College of Cardiology.

[11]  Bernard Chevalier,et al.  Evaluation of the Second Generation of a Bioresorbable Everolimus Drug-Eluting Vascular Scaffold for Treatment of De Novo Coronary Artery Stenosis: Six-Month Clinical and Imaging Outcomes , 2010, Circulation.

[12]  Hiram G Bezerra,et al.  Angiographic, IVUS and OCT evaluation of the long-term impact of coronary disease severity at the site of overlapping drug-eluting and bare metal stents: a substudy of the ODESSA trial , 2010, Heart.

[13]  G. Biondi-Zoccai,et al.  Percutaneous coronary intervention for small vessel coronary artery disease. , 2010, Cardiovascular revascularization medicine : including molecular interventions.

[14]  Ole Fröbert,et al.  Differences in restenosis rate with different drug-eluting stents in patients with and without diabetes mellitus: a report from the SCAAR (Swedish Angiography and Angioplasty Registry). , 2009, Journal of the American College of Cardiology.

[15]  Leslie A. Coleman,et al.  XIENCE V™ Everolimus‐Eluting Coronary Stent System: A Preclinical Assessment , 2009 .

[16]  R. Virmani,et al.  Endothelial cell recovery between comparator polymer-based drug-eluting stents. , 2008, Journal of the American College of Cardiology.

[17]  Patrick W Serruys,et al.  A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial , 2008, The Lancet.

[18]  G. Wilson,et al.  Overlapping paclitaxel-eluting stents: long-term effects in a porcine coronary artery model. , 2007, Cardiovascular research.

[19]  Frank Litvack,et al.  The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES). , 2005, Journal of the American College of Cardiology.

[20]  R. Virmani,et al.  Differential Response of Delayed Healing and Persistent Inflammation at Sites of Overlapping Sirolimus- or Paclitaxel-Eluting Stents , 2005, Circulation.

[21]  R. Virmani,et al.  Drug eluting stents: are human and animal studies comparable? , 2003, Heart.

[22]  A. Kastrati,et al.  [Intracoronary Stenting and Angiographic Results Strut Thickness Effect on Restenosis Outcome (ISAR-STEREO) Trial]. , 2012, Vestnik rentgenologii i radiologii.

[23]  A. Kastrati,et al.  Intracoronary Stenting and Angiographic Results: Strut Thickness Effect on Restenosis Outcome (ISAR-STEREO) Trial , 2001, Circulation.

[24]  J J Wentzel,et al.  Relationship Between Neointimal Thickness and Shear Stress After Wallstent Implantation in Human Coronary Arteries , 2001, Circulation.

[25]  C. Bauters,et al.  Restenosis after coronary angioplasty. , 1995, European heart journal.

[26]  Spencer B. King,et al.  Restenosis After Coronary Angioplasty: Potential Biologic Determinants and Role of Intimal Hyperplasia , 1989 .

[27]  Patrick W Serruys,et al.  From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade? , 2012, European heart journal.

[28]  B. Gersh,et al.  A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods , 2010 .